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Emricasan Ameliorates Portal 
Hypertension and Liver Fibrosis in 
Cirrhotic Rats Through a  
Hepatocyte-Mediated Paracrine Mechanism
Jordi Gracia-Sancho,1-3 Nicolò Manicardi,1 Martí Ortega-Ribera,1 Raquel Maeso-Díaz,1 Sergi Guixé-Muntet,1,3  
Anabel Fernández-Iglesias,1,2 Diana Hide,1,2 Héctor García-Calderó,1,2 Zoe Boyer-Díaz,4 Patricia C. Contreras,5 Alfred Spada,5 and 
Jaime Bosch1-3
In cirrhosis, liver microvascular dysfunction is a key factor increasing hepatic vascular resistance to portal blood 
f low, which leads to portal hypertension. De-regulated inf lammatory and pro-apoptotic processes due to chronic 
injury play important roles in the dysfunction of liver sinusoidal cells. The present study aimed at characterizing the 
effects of the pan-caspase inhibitor emricasan on systemic and hepatic hemodynamics, hepatic cells phenotype, and 
underlying mechanisms in preclinical models of advanced chronic liver disease. We investigated the effects of 7-day 
emricasan on hepatic and systemic hemodynamics, liver function, hepatic microcirculatory function, inf lammation, 
fibrosis, hepatic cells phenotype, and paracrine interactions in rats with advanced cirrhosis due to chronic CCl4 
administration. The hepato-protective effects of emricasan were additionally investigated in cells isolated from 
human cirrhotic livers. Cirrhotic rats receiving emricasan showed significantly lower portal pressure than vehicle-
treated animals with no changes in portal blood f low, indicating improved vascular resistance. Hemodynamic im-
provement was associated with significantly better liver function, reduced hepatic inf lammation, improved phenotype 
of hepatocytes, liver sinusoidal endothelial cells, hepatic stellate cells and macrophages, and reduced fibrosis. In vitro 
experiments demonstrated that emricasan exerted its benefits directly improving hepatocytes’ expression of specific 
markers and synthetic capacity, and ameliorated nonparenchymal cells through a paracrine mechanism mediated by 
small extracellular vesicles released by hepatocytes. Conclusion: This study demonstrates that emricasan improves 
liver sinusoidal microvascular dysfunction in cirrhosis, which leads to marked amelioration in fibrosis, portal hyper-
tension and liver function, and therefore encourages its clinical evaluation in the treatment of advanced chronic liver 
disease. (Hepatology Communications 2019;3:987-1000).
Advanced chronic liver disease (ACLD) is characterized by the presence of regenerative nodules surrounded by fibrous septa, causing a 
marked architectural distortion, eventually leading to 
portal hypertension and liver failure.(1,2) Progression 
of cirrhosis encompasses multiple coordinated cellular 
de-regulations, including initial injuries to parenchy-
mal and endothelial cells, which lead to hepatocyte 
cell death and sinusoidal dysfunction, activation of 
hepatic stellate cells and resident macrophages, and 
Abbreviations: α-SMA, α–smooth muscle actin; ACLD, advanced chronic liver disease; cGMP, cyclic guanosine monophosphate; col1α1, collagen 
1α; eNOS, endothelial nitric oxide synthase; ET-1, endothelin 1; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HMϕ, hepatic macrophage; 
HSC, hepatic stellate cell; HVR, hepatic vascular resistance; lEV, large extracellular vesicle; IL, interleukin; LSEC, liver sinusoidal endothelial 
cell; MAP, mean arterial pressure; mRNA, messenger RNA; NO, nitric oxide; PBF, portal blood flow; PBS, phosphate-buffered saline; PP, portal 
pressure; sEV, small extracellular vesicle.
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recruitment of other immune cells.(3,4) Intercellular 
communication between parenchymal and nonparen-
chymal cells further contributes to progressive fibro-
genesis and aggravates ACLD. Indeed, it has been 
described that, in response to injury, hepatocytes 
release damage-associated molecular patterns and 
other soluble and microencapsulated components that 
are able to affect neighboring cells.(5,6) Such cross-
talk is important for both cirrhosis progression and 
improvement. In fact, previous studies have demon-
strated that amelioration of a specific liver cell type, 
such as the sinusoidal endothelium, paracrinally 
improves other cells such as hepatic stellate cells.(7-9) 
Nevertheless, little is known about the possibility that 
the improvement in hepatocytes may exert beneficial 
effects on other liver cells in the context of ACLD.
Improvement of ACLD might be accomplished 
with the cessation of injury(10) or by drug-induced 
amelioration of hepatic cells.(11) Unfortunately, cur-
rent options to improve ACLD and its main clinical 
complications are limited,(3,11) and although statins 
have shown beneficial effects on portal hypertension 
and survival, the risk reduction afforded by these and 
other agents is limited,(12,13) indicating that new ther-
apeutic strategies are warranted.
Emricasan (IDN-6556) is an irreversible pan-
caspase inhibitor that primarily targets the liver when 
orally administered,(14) and is being investigated 
in clinical trials for chronic liver disease and por-
tal hypertension after pilot studies in patients with 
chronic hepatitis C suggested a beneficial effect on 
liver function as well as on portal pressure in patients 
with severe portal hypertension.(15-18) Previous pre-
clinical work has shown that inhibition of hepato-
cyte cell death using caspase inhibitors protects the 
liver from acute injury,(19) in scenarios of chronic liver 
disease with mild fibrosis(20) or in cholestatic liver 
injury.(21) Nevertheless, the possible beneficial effects 
of this therapeutic option in models of ACLD and 
portal hypertension are mostly unknown.
The main objective of the present study was to 
characterize the effects of emricasan on liver hemody-
namic and fibrosis in animals with ACLD. Secondary 
aims included the understanding of the underlying 
mechanisms of emricasan in experiments using liver 
cells both from rodent and human cirrhotic livers.
Materials and Methods
animal moDel oF aDVanCeD 
CHRoniC liVeR Disease
Cirrhosis of the liver was induced in male Wistar 
rats by chronic inhalation of CCl4 (Sigma-Aldrich, 
St. Louis, MO), together with phenobarbital in the 
drinking water. When rats developed ascites, approx-
imately after 12-14 weeks, toxicants administration 
was stopped and treatment started 1 week later.(22) 
Animals were kept in environmentally controlled ani-
mal facilities. All procedures were approved by the 
Laboratory Animal Care and Use Committee of the 
University of Barcelona and were conducted in accor-
dance with the European Community guidelines for 
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the protection of animals used for experimental and 
other scientific purposes (EEC Directive 86/609).
The personnel who prepared and administered treat-
ments and those who performed the experimental stud-
ies were different. For maintaining investigator blinding 
during assessment of the results, the treatment’s codes 
were not open until completion of the study.
CHaRaCteRiZation oF 
CHRoniC liVeR Disease Rats 
tReateD WitH emRiCasan
emricasan administration
Cirrhotic rats received either emricasan (10 mg/kg/day; 
per os; n = 20) or vehicle (0.9% dimethylcarboxycellu-
lose; per os; n = 20) for 7 days. The dose was selected 
based on a conversion calculation starting from the 
dose used in humans and in previous preclinical 
publications.(20,21)
In Vivo Hemodynamics
Rats (n = 12 per group) were anesthetized with keta-
mine hydrochloride (100 mg/kg; Merial Laboratories, 
Duluth, GA) plus midazolam (5 mg/kg; Laboratorios 
Reig Jofré, Toledo, Spain) intraperitoneally. A tra-
cheostomy was performed and a polyethylene tube 
PE-240 was inserted into the trachea to ensure a 
patent airway. PE-50 catheters were introduced into 
the femoral artery to measure mean arterial pressure 
(MAP; mmHg) and into the ileocolic vein to measure 
portal pressure (PP; mmHg). A perivascular ultrasonic 
flow probe (Transonic System, Ithaca, NY) was placed 
around the portal vein, as close as possible to the liver 
to avoid portal-systemic collaterals to measure portal 
blood flow (PBF; mL∙min−1). Hepatic vascular resis-
tance (HVR; mmHg·min·mL−1) was calculated as 
PP/PBF. Blood pressures and flows were registered on 
a multichannel computer-based recorder (Power Lab; 
ADInstruments, Sydney, Australia). Body tempera-
ture of the animals was maintained at 37 ± 0.5°C, and 
hemodynamic data were collected after 20 minutes of 
stabilization.(22,23) Blood serum and plasma samples 
were stored for biochemical analysis.
liver microvascular Function
Immediately after recording in vivo hemodynamics, 
rat livers (n = 8 per group) were isolated and perfused 
with Krebs buffer as previously described.(23,24) The 
perfused rat liver preparation was allowed to sta-
bilize for 20 minutes before vasoactive substances 
were added. Intrahepatic microcirculation was pre-
constricted by adding the α1-adrenergic agonist 
methoxamine (10-4 M; Sigma-Aldrich) to the res-
ervoir, and liver microvascular function was assessed 
as concentration–response curves to cumulative doses 
of acetylcholine (10−7-10−5 M; Sigma-Aldrich). Bile 
production was monitored through the entire ex vivo 
perfusion experiment and expressed as μL/min g of 
liver. At the end of the experiment, liver tissue was 
snap-frozen for subsequent molecular analysis.
evaluation of Hepatic Fibrosis and Cell 
Death
Cirrhotic rat livers were fixed in 10% formalin, 
embedded in paraffin, and sectioned. For fibrosis 
quantification, samples were stained with 0.1% sirius 
red, photographed, and analyzed using a microscope 
equipped with a digital camera. The proportion of 
red-stained area was measured using Axiovision 
software.(25) For cell death analysis, deparaffined 
sections were probed with an In Situ Cell Death 
Detection Kit (TUNEL; Roche Diagnostics, Basel, 
Switzerland) according to the manufacturer’s instruc-
tions. Values are expressed as the mean of eight 
fields per sample.
sinusoidal Characterization using 
scanning electron microscopy
In a subgroup of animals (n = 3 per group), 
after obtaining in vivo hemodynamics, livers were 
perfused through the portal vein with a solution 
containing 2.5% glutaraldehyde and 2% paraformal-
dehyde and fixed overnight at 4ºC. Samples were 
washed 3 times with 0.1M cacodylate buffer. Liver 
sections were fixed with 1% osmium in cacodylate 
buffer, dehydrated in ethanol, and dried with hexam-
ethyldisilazane. Six randomly selected blocks from 
each animal were mounted onto stubs, and sput-
ter coated with gold. Ten images per animal were 
acquired at a resolution of ×15,000 using a Jeol 6380 
scanning electron microscope ( JEOL Ltd, Tokyo, 
Japan). Liver sinusoidal fenestrations were quanti-
fied using ImageJ Software (National Institutes of 
Health, New York, NY).(26)
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nitric oxide Bioavailability
Levels of cyclic guanosine monophosphate 
(cGMP), a marker of nitric oxide (NO) bioavail-
ability, were analyzed in liver homogenates using an 
enzyme immunoassay (Cayman Chemical Co., Ann 
Arbor, MI) as previously described.(27)
liVeR Cells isolation anD 
tReatments
Rat
Hepatocytes, liver sinusoidal endothelial cells 
(LSECs), hepatic stellate cells (HSCs), and hepatic 
macrophages (HMϕs) were isolated from cirrhotic 
animals treated with emricasan or vehicle following 
well-standardized protocols.(28) Highly pure (Hep 
97% purity; LSEC 96%; HSC 98%; HMϕ 95%) and 
viable cells (all above 90%) were used. No differences 
in cell viability were observed comparing both groups 
of rats.
In additional mechanistic experiments, primary 
rat cirrhotic hepatocytes were pretreated for 24 hours 
with emricasan (50 μM) or vehicle (0.01% DMSO), 
washed twice with phosphate-buffered saline (PBS), 
and incubated with fresh media. After 24 hours, the 
preconditioned media was centrifuged at 2000 g to 
remove apoptotic bodies and added to primary rat cir-
rhotic HSCs, LSECs, and HMϕs for 24 hours. The 
phenotype of nonparenchymal cells was determined 
in five independent experiments.
To further understand the intercellular crosstalk in 
response to emricasan, the main subfractions of the 
cell secretome (i.e., large extracellular vesicles [lEVs] 
and small extracellular vesicles [sEVs]) were purified 
from hepatocyte preconditioned media and exposed 
to HSCs. Briefly, primary hepatocytes isolated from 
CCl4-cirrhotic rats were cultured for 24 hours in 
vesicle-depleted media supplemented with emricasan 
(50 μM) or vehicle, washed twice with PBS, and then 
incubated with fresh microvesicle-free media for 
24 hours. Supernatants were collected, centrifuged at 
2000 g to remove apoptotic bodies, and microvesi-
cle-enriched subfractions were obtained by subsequent 
ultracentrifugations as described.(29) Preparations 
were routinely tested for purity, size, and concentra-
tion using cryo-electron microscopy and nanopar-
ticle tracking analysis.(30) A total of 30 μg of each 
subfraction was added to primary cirrhotic HSCs for 
24 hours (n = 3 independent experiments).
Human
Hepatocytes and HSCs were isolated from liver 
tissue remnants from cirrhotic liver explants (all of 
alcoholic etiology) following standardized proto-
cols.(31) Human hepatic cells were treated in vitro with 
increasing concentrations of emricasan (10-50 μM) or 
vehicle (0.01% DMSO) in conventional culture plates 
or in the ExoLiver platform(31) (n = 5 independent 
experiments).
The ethics committee of the Hospital Clinic de 
Barcelona approved the study protocol (HCB/2018/ 
0028), and sample manipulation and isolation 
procedures were carried out following good laboratory 
practices. In all cases, patients signed an informed 
consent.
pRotein anD messengeR Rna 
eXpRession analysis
Protein expression was determined by western 
blot in hepatic tissue and cell samples using anti-
bodies described in Supporting Table S1. Blots were 
revealed by chemiluminescence, and digital images 
were taken using a luminescent image analyzer LAS-
4000 (General Electric, Little Chalfont, United 
Kingdom). Protein expression was determined by 
densitometric analysis using the Science Lab 2001, 
Multi Gauge V2.1 (Fuji Photo Film, Düsseldorf, 
Germany). Glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) was used for the normalization of 
quantitative densitometry values.
Immunostaining of paraffin-embedded liver sections 
was performed with antibodies described in Supporting 
Table S1 or with PBS as a negative control. Ten fields 
from each slide at ×400 magnification were randomly 
selected, and photographs were done using a fluores-
cence microscope (Olympus, Tokyo, Japan) and quan-
tified with Image J 1.33u software (National Institutes 
of Health). Two blinded independent researchers per-
formed immunostaining quantifications.
Gene expression was analyzed in total RNA from 
all hepatic tissue and cell samples according to the 
manufacturer’s protocol using primers described in 
Supporting Table S2. Values were reported relative to 
the endogenous control GAPDH. All amplification 
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reactions were performed in duplicate, and nuclease- 
free water was used as no template control in the reac-
tion sets.
Results
emRiCasan inHiBits HepatiC 
Cell DeatH anD impRoVes 
liVeR FunCtion in Rats WitH 
aDVanCeD CiRRHosis
Oral administration of emricasan resulted in signif-
icant inhibition of hepatic cell death, as demonstrated 
by marked reductions in caspase-3 activity and overall 
hepatic cell death as measured by TUNEL (Fig. 1). 
Amelioration of hepatic function by emricasan was 
confirmed by improvement in blood tests and a 
marked increase in bile production (Table 1).
emricasan Reduces portal 
Hypertension and Hepatic 
microvascular Dysfunction in Rats 
With advanced Cirrhosis
As shown in Fig. 2A, rats treated with emri-
casan exhibited lower PP than those receiving 
Fig. 1. Effects of emricasan on hepatic cell death. (A) Protein expression of caspases in livers from cirrhotic rats treated with emricasan 
or vehicle (n = 12 per group). (B) Top: Representative images of hematoxylin and eosin staining in livers from (A) (magnification ×5). 
Bottom: Representative images and quantification of hepatic cell death using TUNEL analysis in animals described in (A) 
(magnification ×20). Values represent mean ± standard error of the mean. Abbreviations: emr, emricasan; veh, vehicle.
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vehicle (12.7 ± 0.6 versus 14.9 ± 0.3 mmHg; −14%; 
P < 0.01) without changes in PBF, thus point-
ing to an improved HVR: 0.88 ± 0.09 versus 
1.14 ± 0.12 mmHg·min·mL−1; −23%; P = 0.1). Impor- 
tantly, emricasan did not modify MAP or heart rate. 
Supporting an improved intrahepatic vascular tone, 
ex vivo perfusion experiments revealed that emri-
casan-treated animals exhibited significantly lower 
portal perfusion pressure and ameliorated liver 
microcirculatory dysfunction, as demonstrated by 
enhanced vasodilatory response to incremental con-
centrations of acetylcholine (Fig. 2B).
underlying mechanisms of  
emricasan-mediated improvement in 
Cirrhotic portal Hypertension
As shown in Fig. 3, cirrhotic animals that were 
treated with emricasan showed significantly lower 
liver fibrosis, measured as the percentage of sirius red– 
positive area, as well as expression of collagen 1α (col1α1). 
Improvement in fibrosis was associated with a reduced 
activation of HSCs, demonstrated by a lower expression 
of several activation markers, including α–smooth mus-
cle actin (α-SMA), p-moesin, PDGFRβ, matrix metal-
loproteinases, and tissue inhibitor of metalloproteinases. 
Moreover, a reduction in desmin content was observed, 
suggesting a diminished number of HSCs.
Additionally, emricasan markedly improved the 
hepatic endothelium. Livers from rats receiving 
emricasan showed improved endothelial phenotype, 
taBle 1. eFFeCts oF emRiCasan on 
moRpHometRiC DesCRiptoRs, BioCHemiCal 
paRameteRs, anD Bile pRoDuCtion in Rats 
WitH aDVanCeD CHRoniC liVeR Disease
Vehicle Emricasan P Value
Body weight pretreatment (g) 353 ± 6 367 ± 7 >0.20
Body weight post treatment (g) 367 ± 11 367 ± 12 >0.20
Liver weight (g) 10.6 ± 0.3 10.3 ± 0.5 >0.20
Spleen weight (g) 1.04 ± 0.03 0.99 ± 0.08 >0.20
AST (U/L) 251 ± 51 123 ± 24 0.05
ALT (U/L) 110 ± 29 51 ± 5 0.1
Bilirubin (mg/dL) 0.58 ± 0.17 0.20 ± 0.06 0.1
Albumin (g/L) 22.7 ± 0.7 24.5 ± 1.0 >0.20
Bile (μL·min−1·g−1) 3.4 ± 0.4 7.5 ± 0.5 0.01
Note: Values represent mean ± standard error of the mean (n = 12 
per group for all parameters except n = 8 per group for bile pro-
duction). Italicized values are those statistically significant.
Abbreviations: ALT, alanine aminotransferase; and AST, aspar-
tate aminotransferase.
Fig. 2. Emricasan improves portal hypertension and liver microvascular dysfunction in cirrhosis. (A) PP, PBF, HVR, and MAP 
measured in vivo in cirrhotic rats treated with emricasan or vehicle (n = 12 per group). (B) Portal perfusion pressure and sinusoidal 
vasorelaxation in response to acetylcholine determined in a subpopulation of animals included in (A) (n = 8 per group). Values represent 
mean ± SEM. Abbreviations: PPP, portal perfusion pressure.
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demonstrated by increased endothelial fenestra-
tion, reduction in sinusoidal von Willebrand factor 
(vWF) expression, and improved NO availability, 
shown by higher phospho-endothelial nitric oxide 
synthase (eNOS) expression and higher cGMP con-
tent (Fig. 4A).
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Finally, and considering the importance of inflam-
mation driving both the progression and regression 
of cirrhosis, we characterized the hepatic inflamma-
tory status in cirrhotic animals receiving emricasan 
or vehicle. As shown in Fig. 4B, livers from emri-
casan-treated rats had significantly lower expression of 
diverse pro-inflammatory molecules (such as interleu-
kin [IL] 1, IL-6, and tumor necrosis factor α) as well 
as a reduced number of CD68 positive cells, without 
modifying the expression of anti-inflammatory genes 
or CD163 positive cells, altogether suggest that the 
drug was able to shift the intrahepatic cellular envi-
ronment from a disease progression toward a disease 
resolution phenotype.
emricasan Directly improves 
Hepatocytes phenotype, Which 
leads to paracrine improvement in 
nonparenchymal Cells
Analysis of hepatocytes, LSECs, HSCs, and HMϕs 
freshly isolated from emricasan-treated or vehi-
cle-treated cirrhotic rats revealed that this pan-caspase 
inhibitor was able to improve all cell populations. In fact, 
hepatocytes isolated from emricasan-treated animals 
exhibited significant improvement in the expression of 
different markers and master regulators of hepatocyte 
status, which was accompanied by re-gain of function, 
demonstrated by significantly higher cyp4503a4 activity 
and protein synthesis capacity (Fig. 5A). In addition, 
nonparenchymal cells also exhibited improvement in 
their phenotype, as shown by differential expression 
of HSC markers including α-SMA collagen I and 
PDGFRβ, eNOS and endothelin 1 (ET-1) in LSECs, 
and inducible nitric oxide synthase in HMϕs (Fig. 5B).
In vitro experiments confirmed that cirrhotic 
hepatocytes directly treated with emricasan exhibited 
improved phenotype in comparison to cells receiv-
ing vehicle (Fig. 6A). Interestingly, and although 
emricasan had no direct effect on the phenotype of 
nonparenchymal cells (Supporting Fig. S1), crosstalk 
experiments disclosed a significant improvement in 
the expression of a variety of specific markers when 
incubated with preconditioned medium obtained 
from emricasan-treated hepatocytes (Fig. 6B).
Analysis of the intercellular crosstalk in response to 
emricasan revealed that the sEVs-enriched subfraction 
of the secretome was the mediator of the hepatocyte- 
derived beneficial effects to nonparenchymal cells 
(Fig. 6C). Indeed, HSCs treated with sEVs from 
emricasan-treated hepatocytes exhibited significantly 
reduced expression of the activation markers α-SMA 
and collagen I, in comparison to HSCs treated with 
the same amount of sEVs from vehicle-treated 
hepatocytes. No effects were observed when incubat-
ing cells with lEVs-enriched fractions.
Hepatoprotective effects of emricasan 
are Confirmed in Human liver Cells
The effects of emricasan modulating the pheno-
type of human hepatocytes were investigated in pri-
mary cells cultured under sinusoidal-like conditions 
using the Exoliver platform, a recently developed 
liver-on-a-chip microfluidic device,(31) or in conven-
tional platforms. Figure 7 shows that human cirrhotic 
hepatocytes cultured in vitro and treated with emri-
casan exhibit a marked amelioration in their pheno-
type when compared with vehicle-treated cells, with 
improved expression of HNF4α, abcc3 and slc22a1, 
and higher albumin and urea synthesis, without signs 
of hepatotoxicity. The number of hepatocytes at the 
end of the experiment were not different between 
groups, as indicated by the amount of RNA obtained 
in each experimental condition. Interestingly, the ben-
eficial effects of the drug were not observed in hepato-
cytes undergoing spontaneous de-differentiation due 
to culture in conventional methods (data not shown).
Discussion
In ACLD, increased hepatic vascular resistance 
caused by the development of hepatic microvascular 
Fig. 3. Analysis of the HSC phenotype and liver fibrosis in cirrhotic rats treated with emricasan. (A) Representative images and 
corresponding quantifications of sirius red staining (magnification ×5), and α-SMA ( ×10) and desmin ( ×20) immunohistochemistry 
in livers from cirrhotic rats treated with emricasan or vehicle (n = 12 per group). (B) Messenger RNA (mRNA) and protein expression 
of HSC activation markers in liver tissue from animals described in (A). (C) mRNA expression of extracellular matrix remodeling 
genes in tissues described in (A). Values represent mean ± SEM. Abbreviations: emr, emricasan; mmp, matrix metalloproteinase; tgf β, 
transforming growth factor β; timp, tissue inhibitor of metalloproteinase; veh, vehicle.
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Fig. 4. Effects of emricasan on the liver sinusoidal endothelium and hepatic inf lammation in cirrhosis. (A) Analysis of sinusoidal 
fenestration in terms of porosity and frequency, sinusoidal expression of vWF, expression of phospho-eNOS/eNOS, and cGMP levels 
in livers from cirrhotic rats treated with emricasan or vehicle. (B) Analysis of inf lammatory markers in livers described in (A). Values 
represent mean ± standard error of the mean. All images magnification ×20. Abbreviations: arg, arginase 1; emr, emricasan; SEM, 
scanning electron microscopy; tnfα, tumor necrosis factor α; veh, vehicle.
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dysfunction, fibrosis, and architectural remodeling is 
the main player in the development of portal hyper-
tension. Different preclinical studies have evaluated 
the possibility of reducing hepatic vascular resistance 
using various strategies(32-35); nevertheless, none of 
them have successfully moved to standard bedside 
applications. Therefore, novel strategies that tar-
get the major pathophysiological abnormalities of 
ACLD without causing systemic adverse effects are 
required to improve treatments for patients with por-
tal hypertension.
The present study demonstrates that 1-week emri-
casan treatment leads to significant improvement in 
cirrhotic portal hypertension in a widely accepted pre-
clinical model of ACLD, the induction of decompen-
sated cirrhosis by prolonged CCl4 administration. The 
decrease in PP was not associated with modifications 
in PBF, pointing to decreased hepatic vascular resis-
tance. Importantly, emricasan administration showed 
no apparent hepatic or systemic adverse effects. 
Interestingly, our results are in alignment with a previ-
ous study, demonstrating benefits of this pan-caspase 
inhibitor by decreasing PP in patients with cirrhosis 
and severe portal hypertension.(17)
Underlying mechanisms explaining the improve-
ment in portal hypertension were diverse and included 
benefits on both vascular and architectural compo-
nents of the increased hepatic vascular resistance.(3) 
Liver microvascular dysfunction leads to increased 
hepatic vascular tone, a key factor in PP elevation in 
cirrhosis, and was significantly improved in animals 
treated with emricasan. In addition, cirrhotic liver 
architectural distortion, which mechanically increases 
liver vascular resistance, was also ameliorated as shown 
by a significant diminution in liver fibrosis.
To understand the global improvement in liver 
hemodynamics and fibrosis due to emricasan, we 
evaluated the changes in the phenotype of the three 
Fig. 5. Phenotype of primary liver cells isolated from cirrhotic animals receiving emricasan. (A) Analysis of hepatocyte phenotype in 
terms of expression of key transcription factors and cellular transporters, CYP450 activity, and protein synthesis determined in cells 
isolated from cirrhotic rats treated with emricasan or vehicle. (B) Characterization of nonparenchymal cells isolated from animals 
described in (A). mRNA expression of key cellular markers in HSCs (left), LSECs (middle), and HMϕs (right) (n = 5 independent 
isolations per group). Values represent mean ± standard error of the mean. Abbreviations: emr, emricasan; iNOS, inducible nitric oxide 
synthase; klf, Kruppel-like factor; tgf β, transforming growth factor β; tnfα, tumor necrosis factor α; veh, vehicle.
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major cellular components of the sinusoid (i.e., 
HSCs, LSECs, and HMϕs). Analysis performed 
in liver tissue from emricasan-treated cirrhotic rats 
demonstrated partial de-activation of HSC, and 
improvement in LSEC and HMϕ. The amelioration 
in HSC was evidenced by a decrease in pro-activation 
markers, extracellular matrix components, and prolif-
erative indicators. These data are in agreement with 
previous reports demonstrating antifibrotic effects 
of pan-caspase inhibitors in preclinical models of 
mild injury.(36-38) Our current study, however, further 
demonstrates the ability of emricasan to promote 
fibrosis regression in a model of very advanced liver 
disease, as exemplified by cirrhotic rats with ascites. 
In addition to HSCs, LSECs represent an important 
component of the hepatic sinusoid with essential roles 
Fig. 6. Effects of emricasan on hepatic cell phenotype and underlying paracrine mechanisms. (A) Phenotype of hepatocytes isolated 
from cirrhotic rats and treated in vitro with emricasan or vehicle. (B) Phenotype of HSCs (left), LSECs (middle), and HMϕs (right) 
isolated from cirrhotic rats and treated in vitro with preconditioned media from vehicle-treated or emricasan-treated cirrhotic 
hepatocytes. (C) Left: Analysis of cirrhotic rat HSC phenotype after incubation with lEVs-enriched or sEVs-enriched secretome 
subfractions purified from cirrhotic rat hepatocytes treated with emricasan or vehicle. Dotted line corresponds to mRNA expression 
in HSCs incubated with vehicle-treated hepatocyte secretome subfractions. Right: Protein expression of specific markers of EVs and 
negative controls, and nanoparticle tracking analysis and electron microscopy images from small EVs-enriched preparations (n = 3-5 
independent isolations). Values represent mean ± standard error of the mean. Abbreviations: emr, emricasan; veh, vehicle.
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modulating hepatic vascular tone, inflammation, and 
hemostasis.(3) Herein we describe global improvement 
in the LSEC phenotype and function, as demonstrated 
by increased NO bioavailability, which has import-
ant vasodilatory effects. In addition, emricasan treat-
ment increased sinusoidal porosity, which may lead 
to improved overall liver function due to enhanced 
communication between hepatocytes and the blood 
stream.(6) HMϕ analysis further demonstrated the 
protective effects of emricasan, which promoted a 
change in the phenotype of cirrhotic HMϕ, leading to 
a reduction in M1-like macrophages, with no changes 
in M2-like cells. Importantly, restoration of HMϕ 
balance was accompanied by significant reduction in 
intrahepatic inflammation, in which the improved 
LSEC function may also contribute. Finally, and 
although our results and previous data do not support 
possible interfering effects of long-term emricasan on 
fibrosis resolution or carcinogenesis,(20,39) future stud-
ies should unveil these possibilities.
To further analyze the mechanisms by which 
emricasan improves the phenotype of parenchy-
mal and nonparenchymal cells in the cirrhotic liver, 
we evaluated whether the drug was directly affect-
ing cells or required paracrine interactions between 
the different cellular subpopulations. This informa-
tion is relevant, as it has been demonstrated that 
pathways involving caspases share molecular inter-
mediates with pathways related with intercellular 
communication.(40) Interestingly, emricasan admin-
istration to primary cells isolated from cirrhotic rat 
livers improved the expression of different markers 
of hepatocytes functionality, but had no clear direct 
effects on cultured nonparenchymal cells. Subsequent 
experiments evaluating possible paracrine effects from 
emricasan-treated hepatocytes evidenced a positive 
crosstalk, leading to marked de-activation of HSC, 
together with partial improvements in LSECs and 
HMϕs. These observations are in agreement with 
previous works demonstrating the modulation of 
paracrine effectors in response to pan-caspase inhibi-
tors.(14,36,41) Nevertheless, our study adds a significant 
piece of knowledge in this process. Although previ-
ous work attributed the beneficial paracrine effect 
mediated by pan-caspase inhibitors to a decrease in 
the release of apoptotic bodies, we demonstrate herein 
that hepatocytes receiving emricasan modulate the 
intracellular secretome machinery to beneficially com-
municate with neighboring cells. Importantly, hepato-
cyte-derived sEVs appear to be the main mechanism 
responsible for the paracrine communications in 
response to emricasan. Nevertheless, we cannot dis-
card that other soluble mediators not associated with 
extracellular vesicles may also contribute. Future stud-
ies should unravel the specific molecular mediator(s) 
responsible of this cellular crosstalk. In this regard, 
the sinusoidal-protective effects of emricasan may be 
partly explained by the capability of the drug to mod-
ulate pro-coagulant mediators,(42) thus blunting one 
of the mechanisms in the pathophysiology of cirrhosis 
and portal hypertension.(43,44)
Finally, and aiming at validating our findings in 
the preclinical model into an experimental setting as 
close as possible to human cirrhosis, we evaluated the 
Fig. 7. Effects of emricasan on human cirrhotic hepatocytes. Phenotype of hepatocytes isolated from human cirrhotic livers and treated 
in vitro with emricasan or vehicle (n = 5 independent isolations). Values represent mean ± standard error of the mean. Abbreviations: 
ALT, alanine aminotransferase; AST, aspartate aminotransferase; emr, emricasan; LDH, lactate dehydrogenase; veh, vehicle.
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effects of emricasan modulating the phenotype of pri-
mary cells isolated from cirrhotic human livers cul-
tured in a liver-on-a-chip device. These experiments 
demonstrated a marked improvement in hepatocyte 
phenotype, without signs of toxicity, altogether indi-
cating that the hepatoprotective effects of emricasan 
are also observed in human cirrhosis.
In conclusion, the present study provides infor-
mation in the field of chronic liver disease, showing 
that emricasan administration to cirrhotic animals 
decreases PP and liver fibrosis, thus ameliorating por-
tal hypertension. Underlying mechanisms included 
direct hepatocyte protection and subsequent benefi-
cial paracrine effects on sinusoidal cells. Emricasan 
hepato-protection was further confirmed in human 
cirrhotic liver cells, altogether suggesting that emri-
casan may represent an effective therapeutic approach 
for the treatment of patients with advanced cirrhosis 
and severe portal hypertension.
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